

Coryneforms the Opportunistic Pathogens - An Emerging Challenge for Immunocompetent Individuals

¹Meher Rizvi, ¹Fatima Khan, ¹Adil Raza, ¹Indu Shukla, ¹Abida Malik, ²Syed Ali Raza Rizvi,
³Mohammad Khalid Sherwani, ⁴Kamran Afzal and ⁵Syed Abrar Hasan

¹Department of Microbiology, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, India 202002

²Department of Ophthalmology, Jawaharlal Nehru Medical College and Hospital,
AMU, Aligarh, India 202002

³Department of Orthopaedic Surgery, Jawaharlal Nehru Medical College and Hospital,
AMU, Aligarh, India 202002

⁴Department of Paediatrics, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, India 202002

⁵Department of Otorhinolaryngology, Jawaharlal Nehru Medical College and Hospital,
AMU, Aligarh, India 202002

Abstract: *Coryneforms* have emerged as important pathogens causing severe human infections in immunosuppressed patients. However, it is increasingly being perceived that the pathogenic potential of *Coryneform* bacteria is being underestimated and it is not limited to merely this group of patients. These organisms are reported to cause serious infections such as bacteremia, valvular endocarditis, neurosurgical shunt infections, meningitis, brain abscess, peritonitis, osteomyelitis, septic arthritis, pneumonia, empyema and urinary tract infections. The study was conducted in the Department of Microbiology, Jawaharlal Nehru Medical College and Hospital, Aligarh, INDIA for a period of eight months from August 2007 to March 2008. All the patients in the study were divided into two groups: (i) Immunocompromised (ii) Immunocompetent. Direct microscopic examination was done by Gram staining, followed by culture. All the isolated *Coryneform* species were subjected to antimicrobial susceptibility testing using Kirby bauer disc diffusion method on Mueller Hinton agar incorporated with 5% sheep blood. A total of 2508 samples (68.6%) showed growth on culture. *Coryneforms* were isolated and considered as pathogens in 5.5% samples. Monomicrobial infection of *Corynebacterium* species was more common (69.1%) with surgical site infection (27.3%) as the commonest presentation. *Coryneforms* isolates from the immunocompetent patients accounted for 98(70.5%) isolates, whereas 41(29.5%) isolates were from patients with an immunocompromised status. *C. minutissimum* was the commonest *Coryneform* isolated in both the groups. The other *Coryneform* species isolated were *C. jeikium*, *Microbacterium* species, *C. xerosis*, *C. striatum*, *C. urealyticum*, *C. afermentans*, *C. amycolatum* and *C. ulcerans*. Alarmingly widespread antibiotic resistance was observed among most of the *Coryneforms*. The average sensitivity of the β -lactam antimicrobials being just 55% and the aminoglycosides even less than 50% (48%). Only 67(47.5%) strains were sensitive to flouroquinolones. Linezolid was the only antimicrobial to which all the *Coryneform* isolates included in this study were uniformly sensitive. This study highlights the need for maintaining a high degree of suspicion as far as *Coryneform* infections are concerned. They should not be dismissed as skin commensals in immunocompetent patients without determining their clinical relevance. Sensitizing clinicians about these emerging pathogens and their multidrug resistant nature is also essential.

Key words:

INTRODUCTION

Coryneforms have emerged as important pathogens causing severe human infections in immunosuppressed

patients [1, 2]. However, it is increasingly being perceived that the pathogenic potential of *Coryneform* bacteria is being underestimated and it is not limited to merely this group of patients. Studies relating the pathogenic

potential of *Coryneforms* to the immunocompetent individuals have proved them as well established pathogens [3,4]. Several species such as *Corynebacterium xerosis*, *Corynebacterium amycolatum*, *Corynebacterium striatum*, *Corynebacterium minutissimum*, *Corynebacterium pseudodiphtheriticum*, *Corynebacterium matruchotii*, *Corynebacterium aquaticum*, *Corynebacterium genitalium* and *Corynebacterium pseudogenitalium* have been related to human infections. *Corynebacterium jeikeium* and *Corynebacterium urealyticum* are well established human pathogens exhibiting resistance to several antibiotics [5, 6]. These organisms are reported to cause serious infections such as bacteremia, valvular endocarditis, neurosurgical shunt infections, meningitis, brain abscess, peritonitis, osteomyelitis, septic arthritis, pneumonia, empyema and urinary tract infections [7].

However, reports of the epidemiology of *Coryneforms* from developing countries are few. *Coryneforms* appear to be significant pathogens of tropical countries rather than of temperate areas [8]. There is sparse data from India from where there are only a few case reports [9, 10].

Therefore, this broad based study was designed to study the role of *Coryneforms* as pathogens in immunocompetent along with the immunocompromised individuals and to evaluate the antimicrobial susceptibilities of different genera and species of *Coryneforms* in diverse clinical settings.

MATERIALS AND METHODS

The study was conducted in the Department of Microbiology, Jawaharlal Nehru Medical College and Hospital, Aligarh, INDIA for a period of eight months from August 2007 to March 2008. Detailed clinical history was elicited from the patients and depending on the type of infection; various specimens like cerebrospinal fluid (meningitis and encephalitis), pus, urine (urinary tract infection- UTI), sputum (lower respiratory tract infection- LRTI), throat swabs (upper respiratory tract infection- URTI), eye swabs (conjunctivitis), ear swabs (chronic suppurative otitis media- CSOM), cervical swabs (cervicitis), surgical wound swabs (surgical site infection), joint fluid (synovitis), ascetic fluid, pleural fluid, drains and catheter samples were included in the study making a total of 3653 samples. Empiric treatment was started whenever necessary.

All the patients in the study were divided into two groups: (I) Immunocompromised: patients were

considered to be immunocompromised when they had history of HIV, malignancy, diabetes mellitus or any other chronic disease. Patients without any such history, but age greater than 60 years or a differential cell count showing leucopenia were considered immunocompromised. A total of 987 patients were enrolled in this group. (ii) Immunocompetent: patients without an underlying chronic disease and didn't give any of the above mentioned history were considered to be immunocompetent. A total of 2666 patients were included in this group.

Direct microscopic examination was done by Gram staining, followed by culture on 5% sheep blood agar, MacConkey agar and enrichment was done in brain heart infusion broth with 1% serum. Incubation was done for 18-24 hours at 37°C. Isolated *Corynebacteria* species were considered pathogenic when at least one of the following criteria were met: (I) Clinical history of inflammation, tenderness, purulent discharge with or without fever, (ii) in cases of superficial samples, isolation at least 3 times in samples taken at 3 different times and the presence of polymorphonuclear neutrophils on Gram's staining, (iii) isolation from a deep sample, (iv) in any kind of sample, the presence of Gram positive bacilli within polymorphonuclear neutrophils on gram's staining [11].

Identification of *Coryneform* species was done using standard biochemical methods [12]. All the isolated *Coryneform* species were subjected to antimicrobial susceptibility testing using Kirby bauer disc diffusion method on Mueller Hinton agar incorporated with 5% sheep blood [13]. The antimicrobial agents used were ampicillin 10µg, oxacillin 1µg, cefazolin 30µg, erythromycin 15µg, gentamicin 10µg, amikacin 30µg, chloramphenicol 30µg, tetracycline 30µg, ofloxacin 5µg, vancomycin 30µg, teicoplanin 30µg and linezolid 30µg. In *Staphylococcal* isolates oxacillin (1µg) for the detection of MRSA. Among the Gram negative bacilli screening of possible ESBL production was done by using ceftriaxone (30µg) and cefoperazone (75µg). Those isolates with zone diameters less than 25mm for ceftriaxone and less than 22mm for cefoperazone were subsequently confirmed for ESBL production. Confirmation was done by noting the potentiation of the activity of cefoperazone in the presence of cefoperazone sulbactam [14]. Detection of AmpC betalactamase was done on isolates resistant to ceftriaxone (30µg), cefixime (15µg), cefoperazone (75µg) and cefoperazone sulbactam (75/75µg). Induction of AmpC synthesis was based on the disc approximation assay using imipenem as inducer [14].

Ethical clearance was obtained from the Institutional Ethical Committee of Jawaharlal Nehru Medical College. Informed and written permission was obtained from all patients.

Statistical analysis was done using the Student's t test, chi square test and unpaired Student's t test.

RESULTS

A total of 2508 samples (68.6%) showed growth on culture. *Staphylococcus aureus* (27.9%) was the commonest pathogen isolated during the study, followed by *Escherichia coli* (21.1%), *Pseudomonas aeruginosa* (15.9%) and *Klebsiella pneumoniae* (11.6%). Coryneforms were isolated in (6.8%) of samples, however, (5.5%) of these strains were considered as pathogens and were included in the study (Figure 1).

Monomicrobial infection of *Corynebacterium* species was more common with 96 (69.1%) isolates seen in pure culture and 43 (30.9%) *Coryneform* isolates were associated with polymicrobial infection (Table 1). *Coryneforms* were isolated in 3.7% of the immunocompetent individuals and in 4.1% of the immunocompromised individuals. *Coryneforms* isolates from the immunocompetent patients accounted for 98(70.5%) isolates, whereas 41(29.5%) isolates were from patients with an immunocompromised status (Table 2). Amongst the immunocompromised patients, 19(46.3%) were ICU patients, 13(31.7%) had malignancies, 5(12.2%) were neonates admitted in nursery (one with symptoms of meningitis, one with meningoencephalitis and 3 were preterm babies) and 4(9.7%) had diabetes mellitus.




Fig. 1: Distribution of Various Pathogens Isolated from the Clinical Samples
 CONS- Coagulase negative Staphylococcus species

Surgical site infection (27.3%) was the commonest presentation in patients with *Coryneform* infection, followed by device related infections (11.5%), soft tissue infections (10.1 %) and chronic bone and joint infection (8.6%) and UTI (8.6 %). The lowest isolation rate of *Coryneform* species was from patients with meningitis and breast abscess (1.4%) (Table 3 Please revise Table 3).

Amongst both the immunocompetent as well as immunocompromised individuals *C. minutissimum* was the commonest *Coryneform* isolated (22.3%). The other *Coryneform* species isolated were *C. jeikeium* (17.9%), *Microbacterium* species (8.6%), *C. xerosis* (7.9%), *C. striatum* (7.2%), *C. urealyticum* (6.5%), *C. afermentans* (5.7%), *C. amycolatum* (2.9%) and *C. ulcerans* (1.4%) (Table 2). In most of the patients with surgical site infections, *C. minutissimum* was the commonest isolate

Table 1: Distribution of Coryneform Species in Pure and Mixed Cultures

Coryneform species isolated	No. (%)
In Pure culture	96 (69.1)
Along with one organism	23 (16.6)
Along with two organisms	20 (14.4)
Total	139 (100)

Table 2: Isolation of Coryneform Species in Relation to Immune Status of the Patient

Coryneform species	Immunocompetent No. (%)	Immunocompromised No. (%)	Total No. (%)
<i>C. minutissimum</i>	17(54.8)	14(45.2)	31(22.3)
<i>C. jeikeium</i>	12(48)	13 (52)	25(18.0)
<i>Microbacterium sp</i>	10(83.3)	2(16.7)	12(8.6)
<i>C.xerosis</i>	8(72.7)	3(27.3)	11(7.9)
<i>C.striatum</i>	8(80)	2(20)	10(7.2)
<i>C.urealyticum</i>	9(100)	-	9(6.5)
<i>C.afermentans</i>	8(100)	-	8(5.7)
<i>C. amycolatum</i>	3(75)	1(25)	4(2.9)
<i>C.ulcerans</i>	2(100)	-	2(1.4)
<i>Others</i>	21(77.8)	6(22.2)	27(19.4)
Total	98 (70.5)	41(29.5)	139(100)

Table 3: Isolation of Coryneform Species in Relation to Clinical Presentation in Patients

Coryneform species	Osteomyelitis	Chronic bone and joint infection	Surgical site infections	Urinary Tract Infections	Meningitis	Breast abscess	Peritonitis	Device related infection
<i>C. minutissimum</i>	3	1	15	1	-	1	-	1
<i>C. jeikeium</i>	5	4	5	1	-	1	5	2
<i>Microbacterium sp</i>	-	1	7	-	-	-	-	1
<i>C. xerosis</i>	-	2	-	5	-	-	1	1
<i>C. striatum</i>	-	2	4	-	-	-	-	3
<i>C. urealyticum</i>	-	-	2	3	-	-	2	-
<i>C. afermentans</i>	-	-	-	-	-	-	-	4
<i>C. amycolatatum</i>	1	-	1	-	-	-	-	2
<i>C. ulcerans</i>	-	-	-	-	-	-	-	-
Others	1	2	4	2	2	-	-	2
Total	10(7.2)	12(8.6)	38(27.3)	12(8.6)	2(1.4)	2(1.4)	8(5.7)	16(11.5)

to be continued

Coryneform species	Soft tissue infection	UpperRespiratory Tract Infection	Lower Respiratory Tract Infection	chronic suppurative otitis media	Conjunctivitis	Cervicitis	Umblical tip	TotalNo.(%)
<i>C. minutissimum</i>	8	-	-	-	-	1	-	31(22.3)
<i>C. jeikeium</i>	-	-	-	-	-	-	2	25(18.0)
<i>Microbacterium sp</i>	-	-	-	1	1	-	1	12(8.6)
<i>C. xerosis</i>	1	-	-	-	-	-	1	11(7.9)
<i>C. striatum</i>	1	-	-	-	-	-	-	10(7.2)
<i>C. urealyticum</i>	1	-	-	-	-	-	1	9(6.5)
<i>C. afermentans</i>	-	-	-	4	-	-	-	8(5.7)
<i>C. amycolatatum</i>	-	-	-	-	-	-	-	4(2.9)
<i>C. ulcerans</i>	-	1	1	-	-	-	-	2(1.4)
Others	3	4	2	2	2	-	1	27(19.4)
Total	14(10.1)	5 (3.6)	3 (2.1)	7 (5.0)	3 (2.1)	1 (0.7)	6 (4.3)	139(100)

Table 4: Antibiotic Susceptibility Pattern of Clinically Important Coryneforms

Coryneform species	Ampicillin	Oxacillin	Cefazolin	Erythromycin	Gentamicin	Amikacin	Ofoxacin	Vancomycin	Teicoplanin	Linezolid	Total No.(%)
<i>C. minutissimum</i>	8	10	9	15	4	8	6	24	24	31	31(22.3)
<i>C. jeikeium</i>	8	8	0	9	8	12	19	22	22	25	25(18.0)
<i>Microbacterium sp</i>	0	5	4	5	4	6	3	11	11	12	12(8.6)
<i>C. xerosis</i>	11	11	9	11	9	11	11	11	11	11	11(7.9)
<i>C. striatum</i>	4	5	2	7	4	3	3	10	10	10	10(7.2)
<i>C. urealyticum</i>	5	9	9	1	2	3	2	9	9	9	9(6.5)
<i>C. afermentans</i>	8	8	6	8	8	8	8	8	8	8	8(5.7)
<i>C. amycolatatum</i>	3	4	3	3	2	3	2	4	4	4	4(2.9)
<i>C. ulcerans</i>	2	2	2	2	2	2	2	2	2	2	2(1.4)
Others	25	27	27	22	16	21	11	27	27	27	27(19.4)
Total	74(52.5)	89(63.1)	71(50.4)	83(58.9)	59(41.8)	77(54.6)	67(47.5)	128(92.1)	128(92.1)	139(100)	139(100)

(39.5%), while in patients with osteomyelitis, *C. jeikeium* was the most common (50% revise??). UTI was predominantly caused by *C. xerosis* (41.7%) and *C. urealyticum* (25%) (Table 3).

Results of the antimicrobial susceptibility test showed that among the *S. aureus* isolates, 410 (58.6%) were MSSA and 290 (41.4%) were MRSA. In case of the Gram-negative bacilli, 750(50.5%) were ESBL-producers and 260(17.5%) were AmpC producers.

Alarmingly widespread antibiotic resistance was observed among most of the *Coryneforms* (Table 4). Amongst the β -lactam group of antimicrobials, oxacillin was found to have the best susceptibility profile with (63.1%) sensitivity, followed by ampicillin (52.5%) and cefazolin (50.4%). Amikacin was better among the aminoglycosides with around 13% higher sensitivity than gentamicin [Amikacin- (54.6%), gentamicin- (41.8%)]. Fluoroquinolones had even poorer susceptibility than the

other group of drugs with only 67(47.5%) strains being sensitive. The susceptibility to glycopeptides (teicoplanin and vancomycin) though not 100% but was significantly higher 128(92.1%) than the other antimicrobials. Maximum overall resistance was observed in *C. minutissimum* and *C. jeikeium*. Glycopeptide resistance was observed in 7(22.6%) strains of *C. minutissimum*, 3 (12%) strains of *C. jeikeium* and 1 (8.3%) isolate of *Microbacterium* sp. Linezolid was the only drug to which all the *Coryneform* strains were uniformly sensitive (Table 4). Patients with *Coryneform* infection recovered after empiric treatment was replaced by specific antimicrobials on the basis of susceptibility profile.

DISCUSSION

Corynebacterium species are widely distributed in the environment and are members of skin and mucous membranes [15, 16]. However, in the recent years, recognition of infections with nondiphtheritic *Corynebacterium* species has increased and much new information has become available on many of them. They are usually considered opportunistic pathogens in patients with poor general condition [1, 3]. Few studies have dealt with *Coryneform* infection in healthy immunocompetent people [3, 4].

In this study, we assessed the role of *Coryneform* infection among both immunocompetent as well as immunocompromised individuals. Continue with the following paragraph.

Coryneforms were isolated in (6.8%) of the total samples processed. However, only (5.5%) of these were considered pathogenic and were included in the study. Significantly large number of *Coryneforms* [nearly two-third 98(70.5%)] were isolated from immunocompetent patients. Immunocompromised patients accounted for 41(29.5%) of the *Coryneform* isolates. This finding highlights the role of *Coryneforms* as emerging pathogens in otherwise healthy individuals. *C. minutissimum* was the most common isolate in our study and it predominantly caused infection in immunocompetent people (22.3%). The other commonly isolated *Coryneforms* were *C. jeikeium*, *Microbacterium* sp., *C. xerosis* and *C. striatum*. *C. jeikeium* was isolated as the most common coryneform from orthopaedics and other surgical site infections in another study from our hospital from 2007-2009 [17]. Amongst these, *C. jeikeium* infection was associated more commonly with immunosuppressed patients, while the others infected mostly immunocompetent patients.

However other authors have quoted *C. striatum* as an emerging nosocomial pathogen particularly in the immunocompromised individuals [18, 19].

In the present study, the majority of the patients with *Coryneform* infection had surgical site infection (27.3%) and orthopedic related complaints (15.8%). Two unusual cases of meningitis in immunocompetent patients were noticed in our study. In one the incriminatory pathogen was *Rhodococcus equii* and *Corynebacterium aquaticum* in the other. Both were vancomycin sensitive. One study has reported vancomycin resistant *C. aquaticum* [8].

This study highlights the alarming problem of drug resistance among *Coryneforms*. The average sensitivity of the β -lactam antimicrobials being just 55% and the aminoglycosides even less than 50% (48%). The fluoroquinolones were found to have extremely poor activity against the *Coryneforms* which another study had also reported [20]. Along with resistance to other antimicrobial agents, vancomycin and teicoplanin resistance was observed in 7 strains of *C. minutissimum* (22.6%), 3(12%) isolates of *C. jeikeium* and one (8.3%) strain *Microbacterium* sp. Multidrug resistant character of these bacteria have also been observed in another study [8]. Whereas some studies have quoted uniform sensitivity to the glycopeptides antibiotics [18, 21].

C. minutissimum and *C. jeikeium* were the least sensitive to the various group of drugs followed by *Microbacterium* sp, *C. urealyticum*, *C. amycolatum* and *C. striatum*. Their multidrug resistant character yet again stresses the need to report these *Coryneforms*. It was observed that those bacteria which were vancomycin resistant were also predominantly resistant to other antimicrobials. Linezolid was the only antimicrobial to which all the *Coryneform* isolates included in this study were uniformly sensitive. However until definitive results of susceptibility testing are available vancomycin will continue to be the most recommended treatment for severe *Corynebacterium* infection [22].

This study highlights the need for maintaining a high degree of suspicion as far as *Coryneform* infections are concerned. They should not be dismissed as skin commensals in immunocompetent patients without determining their clinical relevance. We believe that for routine laboratory testing the simple criteria outlined by Funke [5] for clinical relevance should be followed. Sensitizing clinicians about these emerging pathogens and their multidrug resistant nature is also essential. Another cause of concern is the possibility of transfer of drug resistance to *Staphylococcus* as they often share some ecological niche.

Our assessment of *Corynebacterium* isolates showed that several *Corynebacterium* species exhibiting unpredictable antimicrobial resistance might be encountered in patients with varied clinical manifestations. Much more work needs to be done on this enlarging group of this emerging bacteria in order to understand their epidemiology in immunocompetent people, their resistance profile and their virulence potential.

REFERENCES

1. Mikucka, A., E. Gospodarek and M. Bialek, 1997. Opportunistic infections with *Coryneform*. Medical Science Monitor, 3: 154-157. Make references like this style.
2. Young, V.M., W.F. Meyers, M.R. Moody and S.C. Schimpff, 1981. The emergence of *Coryneform* bacteria as a cause of nosocomial infections in compromised hosts. American Journal of Medicine, 70: 646-650.
3. Watkins, D.A., A. Chahine and R.J. Creger, 1993. *Corynebacterium striatum*: a diphtheroid with pathogenic potential. Clinical Infectious Diseases, 17: 21-25.
4. Roux, V., M. Drancourt, A. Stein, P. Riegel, D. Raoult and B. La Scola, 2004. *Corynebacterium* Species Isolated from Bone and Joint Infections identified by 16Sr RNA Gene sequence analysis. Journal of Clinical Microbiology, pp: 2231-2233.
5. Funke, G. and K.A. Bernard, 1999. *Coryneform* Gram Positive Rods. In P.R. Murray, E.J. baron, M.A. Pfaller, C. Tenover, R.H. Yolken (eds.). Manual of Clinical Microbiology, 7th ed. ASM Press. Washington, DC., pp: 319-345.
6. Claeys, G., G. Verschraegen, L. DeSmet, R. Verdonk and H. Claessens, 1986. *Corynebacterium JK (Johnson-Kay strain)* infection of a Kuntsner-nailed tibial fracture. Clinical Orthopaedics and Related Research, 202: 227-229.
7. Brown, A.E., 2000. Other *Corynebacteria* and *Rhodococcus*. In G.L. Mandell, J.E. Bennet and R. Dolin, eds. Principles and practice of infectious diseases. 5th edn, Philedelphia: Churchill Livingstone, pp: 2198-2208.
8. Camello, T.C.F., G.A.L. Mattos, L.C.D. Formiga and E.A. Marquez, 2003. Nondiphtherial *Corynebacterium* species isolated from clinical specimens of patients in a university hospital, Reo De Janeiro, Brazil. Brazilian Journal of Micorbiology, 34: 39-44.
9. Ciraj, A.M., K. Rajani, G. Sreejith, K.L. Shobha and P.S. Rao, 2006. Urinary Tract Infection due to *Arcanobacterium haemolyticum*. Indian Journal of Medical Microbiology, 24: 300.
10. Parija, S.C., V. Kaliaperumal, S.V. Kumar, S. Sujatha and V. Babu, 2005. *Arcanobacterium haemolyticum* associated with pyothorax: case report. BMC Infectious Diseases, pp: 5-68.
11. Horan, T.C., M. Andrus and M. Dudeck, 2008. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in acute care settings. American Journal of Infection Control, 36: 309-332.
12. Tallman, P., E. Muscare, P. Carson, W.H. Eaglstein and V. Falanga, 1997. Initial rate of healing predicts complete healing of venous ulcers. Archives of Dermatology, 133: 1231-1234.
13. Van Rijswijk, L., 1993. Full thickness leg ulcers: patient demographics and predictors of healing. Multi Center Leg Ulcer Study Group. The Journal of Family Practice, 36: 625-632.
14. Rizvi, M., N. Fatima, M. Rashid, I. Shukla, A. Malik, A. Usman and S. Siddiqui, 2009. Extended spectrum AmpC and metallo-beta-lactamases in *Serratia* and *Citrobacter* spp. in a disc approximation assay. Journal of Infection in Developing Countries, 3(4): 285-94.
15. Coyle, M.B. and B.A. Lipsky, 1990. *Coryneform* bacteria in infectious diseases: Clinical and laboratory aspects. Clinical Microbiology Reviews, 3: 227-246.
16. Clarridge, J.E. and C.A. Spigel, 1995. *Corynebacterium* and miscellaneous irregular gram positive rods, *Erysipelothrix* and *Gardnerella*. In: P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover and R.H. Yolken (eds), Manual of Clinical Microbiology. Washington DC. Am Soc. Microbiol., pp: 357-378.
17. Rizvi, M., F. Khan, R. Adil, I. Shukla and A.B. Sabir, 2011. Emergence of coryneforms in osteomyelitis and orthopaedic surgical site infections. AMJ., 4(7): 412-418.
18. Otsukaab, Y., K. Ohkusuaa, Y. Kawamura, S. Babaa, T. Ezakia and S. Kimurao, 2006. Emergence of multidrug resistant *Corynebacterium striatum* as a nosocomial pathogen in long term hospitalised patients with underlying diseases. Diagnostic Microbiol. Infect Dis., 54(2): 109-114.
19. Marull, J. and P.A. Casares, 2008. nosocomial valve endocarditis due to *Corynebacterium striatum*: a case report. Cases Journal, 1: 388.

20. Soriano, F.R., R. Hernandez-Roblas, J. Zapardiel, J.L. Rodriguez-Tudaa, P. Aviles and M. Romero, 1989. Increasing incidence of *Corynebacterium*. EM Journal of Clinical Microbiological Infectious Diseases, 8: 117-118.
21. Funke, G., V. Punter and A. Von-Graevemitz, 1996. Antimicrobial susceptibility patterns of some recently established coryneform bacteria. Antimicrob Agents chemoth, 40(12): 2874-2878.
22. Williams, D.Y., S.T. Selepak and V.J. Gill, 1993. Identification of clinical isolates of non diphtherial *Corynebacterium* species and their antibiotic susceptibility patterns. Diagnostic Microbiology and Infectious Diseases, 17: 23-28.